Advertisement

Topics

The anthelmintic oxyclozanide restores the colistin activity in colistin-resistant Gram-negative bacilli.

08:00 EDT 9th July 2019 | BioPortfolio

Summary of "The anthelmintic oxyclozanide restores the colistin activity in colistin-resistant Gram-negative bacilli."

Due to the significant increase in the antimicrobial resistance of Gram-negative bacilli (GNB), the development of non-antimicrobial therapeutic alternatives, which can be used together with the few and non-optimal available antimicrobial agents such as colistin, has become an urgent need. In this context, the desregulation of the bacterial cell wall could be a therapeutic alternative adjuvant to colistin. The aim of this study was to analyse the activity of oxyclozanide, an anthelmintic drug, in combination with colistin against colistin-susceptible (Col-S) and colistin-resistant (Col-R) GNB. Three reference Col-S strains and 13 Col-R clinical isolates of Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae were studied. Microdilution assays and time-kill curves were performed to examine the activity of oxyclozanide in combination with colistin. Outer membrane proteins (OMPs) profile, membrane permeation and cell wall structure of Col-S and Col-R A. baumannii, P. aeruginosa and K. pneumoniae in presence of oxyclozanide were assessed by SDS-PAGE, fluorescence and transmission electron microscopy, respectively. Oxyclozanide in combination with colistin increases the activity of colistin against Col-S and Col-R A. baumannii, P. aeruginosa and K. pneumoniae. Time-killing curves have showed synergistic activity between oxyclozanide and colistin against these bacterial isolates. Moreover, Col-R A. baumannii, P. aeruginosa and K. pneumoniae in presence of oxyclozanide present higher permeation and disruption in their cell wall than Col-S strains, without modifying their OMPs profile. These data suggest that the combination of oxyclozanide and colistin may be a new alternative for the treatment of Col-R GNB infections.

Affiliation

Journal Details

This article was published in the following journal.

Name: International journal of antimicrobial agents
ISSN: 1872-7913
Pages:

Links

DeepDyve research library

PubMed Articles [13056 Associated PubMed Articles listed on BioPortfolio]

Synergistic combinations of anthelmintic salicylanilides oxyclozanide, rafoxanide, and closantel with colistin eradicates multidrug-resistant colistin-resistant Gram-negative bacilli.

Repurposing nonantibiotic drugs for antimicrobial therapy presents a viable approach to drug discovery. Development of therapeutic strategies that overcome existing resistance mechanisms is important ...

Urinary bactericidal activity of colistin and azidothymidine combinations against mcr-1 positive colistin-resistant Escherichia coli.

A phase 1 clinical study was performed to assess pharmacokinetics and safety of IV administration of colistin-methanesulfonate (CMS) and azidothymidine (AZT) alone and in combination. Seven healthy su...

In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates.

The synergistic activity of eravacycline in combination with colistin on carbapenem-resistant A. baumannii (CRAB) isolates was evaluated in this study. Minimum inhibitory concentrations (MICs) of erav...

The Emergence of Colistin-resistant Klebsiella pneumoniae Strains from Swine in Malaysia.

Colistin is the last line therapy for infections caused by multidrug resistant Gram negative bacteria. The objective of the study was to determine the phenotypic and genotypic characteristics of colis...

Antimicrobial activity of two novel antimicrobial peptides AA139 and SET-M33 against clinically and genotypically diverse Klebsiella pneumoniae isolates with differing antibiotic resistance profiles.

Colistin is an antimicrobial peptide (AMP) used as a drug of last resort, although plasmidal resistance (MCR) has been reported. AA139 and SET-M33 are novel AMPs currently in development for the treat...

Clinical Trials [5362 Associated Clinical Trials listed on BioPortfolio]

Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii

Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline solutio...

Therapy of Ventilator-associated Tracheobronchitis Caused by Gram Negative Bacteria With Nebulized Colistin

The purpose of this study is to determine whether inhaled colistin is effective in the treatment of ventilator associated tracheobronchitis due to gram negative organism susceptible to col...

Colistin-rifampin Combination and Colistin Monotherapy in Extensively Drug-resistant Acinetobacter Baumannii

The investigators aimed to confirm the utility of the synergy test results (E-tesT) in vitro to predict the efficacy and safety of colistin-rifampin combination and colistin monotherapy in...

Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli

Approximately 444 subjects who are greater than or equal to 18 to 95 years of age, are non-pregnant, and are in the inpatient setting of one of the study sites will be evaluated to treatme...

Effect of Aerosolised Colistin in Ventilator Associated Pneumonia

the management of Ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) gram-negative bacilli (GNB) represent a real therapeutic dilemma in intensive care unit (ICU). C...

Medical and Biotech [MESH] Definitions

Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.

Anthelmintic used in grazing animals for fasciola and cestode infestations.

Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.

A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.

A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pneumonia
Pneumonia (bronchopneumonia, lobar pneumonia and double pneumonia) is inflammation (swelling) of the tissue in one or both of your lungs. It is usually caused by an pneumococcal infection caused by bacteria called Streptococcus pneumoniae.  However,...


Searches Linking to this Article